3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Calcinosis
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
109
Magnetic Resonance Spectroscopy
52
Bevacizumab
52
Radiotherapy
44
Irinotecan
27
Blood Specimen Collection
19
Surgical Procedures, Operative
16
Radiation
15
Aminolevulinic Acid
15
Carboplatin
13
fluorodopa F 18
12
Nivolumab
12
Radiotherapy, Intensity-Modulated
11
Carmustine
11
Radiosurgery
10
Magnetic Resonance Imaging
10
pembrolizumab
9
Topotecan
9
Specimen Handling
9
Everolimus
9
Erlotinib Hydrochloride
9
Biopsy
9
poly ICLC
8
Surveys and Questionnaires
8
Standard of Care
8
Etoposide
8
Drug Therapy
8
Lomustine
7
Filgrastim
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioma
×
Pharmacogenomic Variants
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled